Topotecan: Incorporating it into the treatment of solid tumors

Oncologist

Volumn 3, Issue 1, 1998, Pages 1-3

  Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; IRINOTECAN; LURTOTECAN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0031883607     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-1-1     Document Type: Review

References (16)

1. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxidty. The Oncologist 1998;3:4-10.
2. Brahmer JR, Ettinger DS. The role of topotecan in the treatment of small cell lung cancer. The Oncologist 1998;3:11-14.
3. Gordon A, Bookman M, Malmstrom H et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: international topotecan study group trial. Proc Am Soc Clin Oncol 1996;15:282.
4. ten Bokkel Huinik W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
5. Hertzberg RP, Caranfa MJ, Holden KG et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-720.
6. Burris HA, Fields SM. Topoisomerase I inhibitors: an overview of the camptothecin analogs. Hem One Clin of NA 1994;8:333.
7. O'Reilly S, Rowinsky EK, Slichenmeyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88:817-824.
8. O'Reilly S, Rowinsky EK, Slichenmeyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-3073.
9. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
10. Schiller JH, Kim K, Hutson P et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14:2345-2352.
11. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
12. Eckardt J et al. Topotecan as a second-line therapy in patients with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996;7(suppl 5):107a.
13. Jett JR, Day R, Levitt M et al. Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cane 1997;18:13a.
14. Creemers GJ, Gerrits CJH, Eckardt JR et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997;15:1087-1093.
15. Gerrits CJH, Bums H, Schellens JHM et al. Ten days once daily and twice daily dosing of oral topotecan: a phase I and pharmacology study in adult patients with solid tumors. Clin Cancer Res 1997 (in press).
16. Gerrits CJH, Burris H, Schellens JHM et al. Five days of oral topotecan (Hycamtin®), a phase I and pharmacologic study in adult patients with solid tumors. J Clin Oncol 1997 (in press).